血清尿酸与非糖尿病患者的胰岛素抵抗有关
Janis Timsans1,2, Jenni Kauppi3, Vappu Rantalaiho2,4,5
1Department of Rheumatology, Päijät-Häme Central Hospital, Wellbeing Services County of Päijät-Häme, 15850 Lahti, Finland.
Journal of clinical medicine
|April 26, 2025
概括
血清尿酸 (SUA) 升高与老年人更高的禁食血葡萄糖和胰岛素抵抗有关. 管理SUA可能有助于预防葡萄糖代谢障碍及其并发症.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 内分泌学 在内分泌学.
- 老年学是指老年学的学科.
背景情况:
- 葡萄糖代谢障碍对发病率和死亡率有很大影响.
- 血清尿酸 (SUA) 的升高与心脏代谢问题,并发症和死亡率有关.
- 老年人中SUA和葡萄糖代谢标志物之间的关系需要进一步研究.
研究的目的:
- 探索血清尿酸 (SUA) 和快速血葡萄糖 (FPG),胰岛素水平和胰岛素抵抗之间的关联.
- 分析芬兰老年人群中的这些关系.
主要方法:
- 利用了GOAL (Lahti地区的良好老龄化) 研究的数据,这是一个前性,基于人口的群体,包括2322名年龄在52-76岁之间的非糖尿病芬兰人.
- 收集了关于SUA,FPG,胰岛素水平,胰岛素耐药性 (HOMA-IR),并发症,生活方式和社会经济因素的数据.
- 超尿血症的定义是SUA>410μmol/L,而胰岛素抵抗的定义是HOMA-IR ≥2.65.
主要成果:
- 在SUA和FPG,胰岛素水平和胰岛素抵抗之间发现了统计学上显著的,经性别,年龄和BMI调整的关系.
- 较高的SUA水平与HOMA-IR增加相关 (调整后β=0.21),急剧上升超过400μmol/L.
- 患胰岛素抵抗的概率与SUA水平直接相关.
结论:
- 超尿路血症与老年人高FPG和胰岛素耐药性有关.
- 治疗高尿血症对于管理葡萄糖代谢障碍及其心脏代谢后果很重要.
- 进一步的研究应该调查高尿血症治疗在预防葡萄糖代谢障碍方面的潜在作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
136
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
136
Dipeptidyl Peptidase 4 Inhibitors
125
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
125
Oral Hypoglycemic Agents: Sulfonylureas
154
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
154
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Diabetes: Symptoms, Diagnosis, and Complications
475
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
475
Insulin: Dosing Regimen and Adverse Effects
125
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
125


